サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1769768

遅発性ジスキネジア治療薬の世界市場レポート2025年

Tardive Dyskinesia Therapeutics Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
遅発性ジスキネジア治療薬の世界市場レポート2025年
出版日: 2025年07月07日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

遅発性ジスキネジア治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は7.2%で、41億1,000万米ドルに成長する見込みです。この成長予測に寄与する治療要因としては、精神疾患の負担の増加、研究開発イニシアチブの急増、製薬会社からの投資の増加、個別化治療アプローチへの傾斜の増加、ヘルスケアインフラの強化などが挙げられます。この期間に予測される主な動向には、製薬企業と研究機関の戦略的提携、長時間作用型製剤の開発、ジェネリック医薬品の導入、希少疾病用医薬品（オーファンドラッグ）のような規制上のメリット、ドラッグデリバリー技術の革新などがあります。

精神疾患の有病率の上昇は、今後数年間の遅発性ジスキネジア治療薬市場の成長を牽引すると予想されます。人の思考、感情、行動、日常機能に影響を与えるメンタルヘルス障害は、社会的孤立の拡大により増加しています。デジタル・コミュニケーションの普及とペースの速いライフスタイルの要求により、有意義な対面での交流が減少し、孤独感や感情的緊張の高まりにつながっています。遅発性ジスキネジア治療薬は、長期にわたる抗精神病薬の使用によって生じる不随意運動症状を管理することで、精神疾患を持つ患者を支援する上で重要な役割を果たしています。その結果、治療のアドヒアランスと生活の質全体が向上します。例えば、2024年、全米精神疾患同盟（National Alliance on Mental Illness）は、米国の18～44歳の個人において、精神病スペクトラムと気分障害が年間約60万件の入院の原因となっていると報告しています。その結果、精神疾患の発生が増加していることが、遅発性ジスキネジア治療薬市場を推進する重要な要因となっています。

遅発性ジスキネジア治療薬市場の主要企業は、体内の薬物レベルをより安定させるために、1日1回投与の治療オプションなどの先進製品の開発に注力しています。こうした1日1回治療により、投薬スケジュールが簡素化され、患者のコンプライアンスも向上します。2024年5月、イスラエルに本社を置くバイオ医薬品会社テバ・ファーマシューティカル・インダストリーズ・リミテッドは、ハンチントン病に伴う遅発性ジスキネジアと振戦の成人患者を対象としたオーステドXR錠の米国FDA承認を取得しました。AUSTEDO XRは、1日1回の服用で効果的に症状をコントロールすることができ、現在、30mg、36mg、42mg、48mgの4つの強度で提供されています。この製剤の有効性は、極めて重要な臨床試験を通じて検証されており、患者ケアの利便性とアドヒアランスを向上させる役割が強調されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の遅発性ジスキネジア治療薬：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の遅発性ジスキネジア治療薬市場：成長率分析
  • 世界の遅発性ジスキネジア治療薬市場の実績：規模と成長, 2019-2024
  • 世界の遅発性ジスキネジア治療薬市場の予測：規模と成長, 2024-2029, 2034F
  • 世界の遅発性ジスキネジア治療薬：総潜在市場規模（TAM）

第6章 市場セグメンテーション

  • 世界の遅発性ジスキネジア治療薬市場：薬物別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • デュテトラベナジン
  • バルベナジン
  • その他の薬物
  • 世界の遅発性ジスキネジア治療薬市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 固形剤形
  • タブレット
  • カプセル
  • 液体剤形
  • 注射
  • 世界の遅発性ジスキネジア治療薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 抗精神病薬誘発性遅発性ジスキネジア
  • その他の薬剤誘発性遅発性ジスキネジア
  • 特発性遅発性ジスキネジア
  • 世界の遅発性ジスキネジア治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院
  • クリニック
  • 専門治療センター
  • 在宅ケア環境
  • 世界の遅発性ジスキネジア治療薬市場、デュテトラベナジン、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
  • 剤形
  • 治療法
  • 流通チャネル
  • 世界の遅発性ジスキネジア治療薬市場、バルベナジン、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
  • 剤形
  • 患者の年齢層
  • 流通チャネル
  • 世界の遅発性ジスキネジア治療薬市場、その他の医薬品、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
  • 薬物のクラスまたはタイプ
  • 剤形
  • 治療期間

第7章 地域別・国別分析

  • 世界の遅発性ジスキネジア治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界の遅発性ジスキネジア治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 遅発性ジスキネジア治療薬市場：競合情勢
  • 遅発性ジスキネジア治療薬市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Otsuka Pharmaceutical Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Lundbeck A/S
  • Amneal Pharmaceuticals Inc.
  • Lupin Pharmaceuticals Inc.
  • Neurocrine Biosciences Inc.
  • Luye Pharma Ltd.
  • Lannett Co. Inc.
  • SteriMax Inc.
  • Zydus Cadila Healthcare Ltd.
  • Adamas Pharmaceuticals Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • SOM Biotech Ltd.
  • Addex Therapeutics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 遅発性ジスキネジア治療薬市場2029：新たな機会を提供する国
  • 遅発性ジスキネジア治療薬市場2029：新たな機会を提供するセグメント
  • 遅発性ジスキネジア治療薬市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r36086

Tardive dyskinesia therapeutics are treatments aimed at alleviating or controlling the involuntary, repetitive movements associated with this neurological condition. These therapies focus on addressing the neurological disruptions commonly linked to long-term use of specific medications. Their primary objective is to enhance the patient's quality of life by decreasing the intensity and occurrence of motor symptoms, improving functional capabilities, and preventing chronic complications.

Key medications in the tardive dyskinesia therapeutics market include deutetrabenazine, valbenazine, and others. Deutetrabenazine, a vesicular monoamine transporter type 2 (VMAT2) inhibitor, is specifically utilized to manage involuntary movements related to tardive dyskinesia. It is available in various forms such as solid dosage (tablets and capsules), liquid forms, and injections. The drug is applied in cases of antipsychotic-induced tardive dyskinesia, other drug-induced types, and idiopathic tardive dyskinesia. It is administered across multiple end-user environments including hospitals, clinics, specialty treatment centers, and homecare settings.

The tardive dyskinesia therapeutics market research report is one of a series of new reports from The Business Research Company that provides tardive dyskinesia therapeutics market statistics, including tardive dyskinesia therapeutics industry global market size, regional shares, competitors with a tardive dyskinesia therapeutics market share, detailed tardive dyskinesia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the tardive dyskinesia therapeutics industry. This tardive dyskinesia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tardive dyskinesia therapeutics market size has grown strongly in recent years. It will grow from $2.90 billion in 2024 to $3.12 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. This growth during the historical period can be linked to an increasing prevalence of tardive dyskinesia, a rising global population affected by schizophrenia and bipolar disorder, better awareness and improved diagnostic practices, heightened use of both atypical and typical antipsychotic medications, and an expanding aging population.

The tardive dyskinesia therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.11 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. Factors contributing to this anticipated growth include the escalating burden of mental health disorders, a surge in R&D initiatives, heightened investments from pharmaceutical firms, an increasing inclination towards personalized treatment approaches, and enhanced healthcare infrastructure. Key trends projected for this period include strategic alliances between pharmaceutical companies and research institutions, development of long-acting formulations, introduction of generic options, regulatory benefits like orphan drug status, and innovations in drug delivery technologies.

The rising prevalence of mental health disorders is expected to drive the growth of the tardive dyskinesia therapeutics market in the coming years. Mental health disorders, which impact a person's thoughts, emotions, behaviors, or daily functioning, are increasing due to growing social isolation. The widespread adoption of digital communication and the demands of fast-paced lifestyles have reduced meaningful face-to-face interactions, leading to heightened feelings of loneliness and emotional strain. Tardive dyskinesia therapeutics play a crucial role in supporting individuals with mental health conditions by managing involuntary movement symptoms resulting from long-term antipsychotic use. This, in turn, enhances treatment adherence and overall quality of life. For example, in 2024, the National Alliance on Mental Illness reported that among U.S. individuals aged 18-44, psychosis spectrum and mood disorders are responsible for nearly 600,000 hospitalizations annually. As a result, the increasing occurrence of mental health disorders is a significant factor propelling the tardive dyskinesia therapeutics market.

Leading companies in the tardive dyskinesia therapeutics market are concentrating on the development of advanced products such as once-daily treatment options to ensure more consistent drug levels in the body. These once-daily treatments simplify medication schedules and enhance patient compliance. In May 2024, Teva Pharmaceutical Industries Limited, an Israel-based biopharmaceutical company, received U.S. FDA approval for AUSTEDO XR tablets, designed for adults with tardive dyskinesia and chorea associated with Huntington's disease. AUSTEDO XR provides effective symptom control through a single daily dose and is now offered in four strengths: 30 mg, 36 mg, 42 mg, and 48 mg. The formulation's efficacy has been validated through pivotal clinical trials, emphasizing its role in improving convenience and adherence in patient care.

In February 2024, Teva Pharmaceutical Industries Limited entered a partnership with Jiangsu Nhwa Pharmaceutical Co. Ltd. to promote and distribute AUSTEDO in China. This collaboration leverages Nhwa's established presence in China's neuropsychiatric health sector to broaden access to AUSTEDO. The drug is recognized as the first VMAT2 inhibitor approved by the U.S. FDA for treating tardive dyskinesia and Huntington's disease-related chorea in adults. Jiangsu Nhwa Pharmaceutical Co. Ltd. is a pharmaceutical company based in China.

Major players in the tardive dyskinesia therapeutics market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Lundbeck A/S, Amneal Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Neurocrine Biosciences Inc., Luye Pharma Ltd., Lannett Co. Inc., SteriMax Inc., Zydus Cadila Healthcare Ltd., Adamas Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, SOM Biotech Ltd., Addex Therapeutics.

North America was the largest region in the tardive dyskinesia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tardive dyskinesia therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tardive dyskinesia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tardive dyskinesia therapeutics market consists of revenues earned by entities by providing services such as drug discovery, clinical trial management, formulation services, and pharmacovigilance. The market value includes the value of related goods sold by the service provider or included within the service offering. The tardive dyskinesia therapeutics market also includes sales of adjunctive medications, patient monitoring devices, drug delivery systems, and screening tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tardive Dyskinesia Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tardive dyskinesia therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tardive dyskinesia therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tardive dyskinesia therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Drug: Deutetrabenazine; Valbenazine; Other Drugs
  • 2) By Product Type: Solid Dosage Forms; Tablets; Capsules; Liquid Dosage Form; Injection
  • 3) By Application: Antipsychotic-Induced Tardive Dyskinesia; Other Drug-Induced Tardive Dyskinesia; Idiopathic Tardive Dyskinesia
  • 4) By End-User: Hospitals; Clinics; Specialty Treatment Centers; Homecare Settings
  • Sub Segments:
  • 1) By Deutetrabenazine: Dosage Forms; Line Of Therapy; Distribution Channel
  • 2) By Valbenazine: Dosage Forms; Patient Age Group; Distribution Channel
  • 3) By Other Drugs: Drug Class Or Type; Dosage Forms; Treatment Duration
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson; AbbVie Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Tardive Dyskinesia Therapeutics Market Characteristics

3. Tardive Dyskinesia Therapeutics Market Trends And Strategies

4. Tardive Dyskinesia Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Tardive Dyskinesia Therapeutics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Tardive Dyskinesia Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Tardive Dyskinesia Therapeutics Market Growth Rate Analysis
  • 5.4. Global Tardive Dyskinesia Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Tardive Dyskinesia Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Tardive Dyskinesia Therapeutics Total Addressable Market (TAM)

6. Tardive Dyskinesia Therapeutics Market Segmentation

  • 6.1. Global Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Deutetrabenazine
  • Valbenazine
  • Other Drugs
  • 6.2. Global Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Solid Dosage Forms
  • Tablets
  • Capsules
  • Liquid Dosage Form
  • Injection
  • 6.3. Global Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antipsychotic-Induced Tardive Dyskinesia
  • Other Drug-Induced Tardive Dyskinesia
  • Idiopathic Tardive Dyskinesia
  • 6.4. Global Tardive Dyskinesia Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Clinics
  • Specialty Treatment Centers
  • Homecare Settings
  • 6.5. Global Tardive Dyskinesia Therapeutics Market, Sub-Segmentation Of Deutetrabenazine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Dosage Forms
  • Line Of Therapy
  • Distribution Channel
  • 6.6. Global Tardive Dyskinesia Therapeutics Market, Sub-Segmentation Of Valbenazine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Dosage Forms
  • Patient Age Group
  • Distribution Channel
  • 6.7. Global Tardive Dyskinesia Therapeutics Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Drug Class Or Type
  • Dosage Forms
  • Treatment Duration

7. Tardive Dyskinesia Therapeutics Market Regional And Country Analysis

  • 7.1. Global Tardive Dyskinesia Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Tardive Dyskinesia Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Tardive Dyskinesia Therapeutics Market

  • 8.1. Asia-Pacific Tardive Dyskinesia Therapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Tardive Dyskinesia Therapeutics Market

  • 9.1. China Tardive Dyskinesia Therapeutics Market Overview
  • 9.2. China Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Tardive Dyskinesia Therapeutics Market

  • 10.1. India Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Tardive Dyskinesia Therapeutics Market

  • 11.1. Japan Tardive Dyskinesia Therapeutics Market Overview
  • 11.2. Japan Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Tardive Dyskinesia Therapeutics Market

  • 12.1. Australia Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Tardive Dyskinesia Therapeutics Market

  • 13.1. Indonesia Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Tardive Dyskinesia Therapeutics Market

  • 14.1. South Korea Tardive Dyskinesia Therapeutics Market Overview
  • 14.2. South Korea Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Tardive Dyskinesia Therapeutics Market

  • 15.1. Western Europe Tardive Dyskinesia Therapeutics Market Overview
  • 15.2. Western Europe Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Tardive Dyskinesia Therapeutics Market

  • 16.1. UK Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Tardive Dyskinesia Therapeutics Market

  • 17.1. Germany Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Tardive Dyskinesia Therapeutics Market

  • 18.1. France Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Tardive Dyskinesia Therapeutics Market

  • 19.1. Italy Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Tardive Dyskinesia Therapeutics Market

  • 20.1. Spain Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Tardive Dyskinesia Therapeutics Market

  • 21.1. Eastern Europe Tardive Dyskinesia Therapeutics Market Overview
  • 21.2. Eastern Europe Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Tardive Dyskinesia Therapeutics Market

  • 22.1. Russia Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Tardive Dyskinesia Therapeutics Market

  • 23.1. North America Tardive Dyskinesia Therapeutics Market Overview
  • 23.2. North America Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Tardive Dyskinesia Therapeutics Market

  • 24.1. USA Tardive Dyskinesia Therapeutics Market Overview
  • 24.2. USA Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Tardive Dyskinesia Therapeutics Market

  • 25.1. Canada Tardive Dyskinesia Therapeutics Market Overview
  • 25.2. Canada Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Tardive Dyskinesia Therapeutics Market

  • 26.1. South America Tardive Dyskinesia Therapeutics Market Overview
  • 26.2. South America Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Tardive Dyskinesia Therapeutics Market

  • 27.1. Brazil Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Tardive Dyskinesia Therapeutics Market

  • 28.1. Middle East Tardive Dyskinesia Therapeutics Market Overview
  • 28.2. Middle East Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Tardive Dyskinesia Therapeutics Market

  • 29.1. Africa Tardive Dyskinesia Therapeutics Market Overview
  • 29.2. Africa Tardive Dyskinesia Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Tardive Dyskinesia Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Tardive Dyskinesia Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Tardive Dyskinesia Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Tardive Dyskinesia Therapeutics Market Competitive Landscape
  • 30.2. Tardive Dyskinesia Therapeutics Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Tardive Dyskinesia Therapeutics Market Other Major And Innovative Companies

  • 31.1. Otsuka Pharmaceutical Co. Ltd.
  • 31.2. Sun Pharmaceutical Industries Ltd.
  • 31.3. Dr. Reddy's Laboratories Ltd.
  • 31.4. Lundbeck A/S
  • 31.5. Amneal Pharmaceuticals Inc.
  • 31.6. Lupin Pharmaceuticals Inc.
  • 31.7. Neurocrine Biosciences Inc.
  • 31.8. Luye Pharma Ltd.
  • 31.9. Lannett Co. Inc.
  • 31.10. SteriMax Inc.
  • 31.11. Zydus Cadila Healthcare Ltd.
  • 31.12. Adamas Pharmaceuticals Inc.
  • 31.13. Mitsubishi Tanabe Pharma Corporation
  • 31.14. SOM Biotech Ltd.
  • 31.15. Addex Therapeutics

32. Global Tardive Dyskinesia Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Tardive Dyskinesia Therapeutics Market

34. Recent Developments In The Tardive Dyskinesia Therapeutics Market

35. Tardive Dyskinesia Therapeutics Market High Potential Countries, Segments and Strategies

  • 35.1 Tardive Dyskinesia Therapeutics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Tardive Dyskinesia Therapeutics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Tardive Dyskinesia Therapeutics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer